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1. Introduction 
The anti-oestrogen, tamoxifen, is an effective 
chemotherapeutic agent in the treatment ofmetastatic 
mammary carcinoma yet its mode of action is not 
understood. We have shown that the inhibitor, at an 
optimal dose of l-2 mg/kg exerts a profound effect 
on the synthesis of uterine RNA measured as incor- 
poration of precursor into acid insoluble material [ 1 
This effect occurred over a totally different time 
course to that induced by oestrogens. Thus, a single 
I. 
administration of oestradiol-170 caused a stimulation 
ofuterine RNAsynthesis which peaked at 7-l 2-times 
control levels, 2-4 h after hormone injection [l-3]. 
Tamoxifen had no effect at 2 h but induced a broad 
peak of stimulated RNA synthesis which lasted from 
12-3 2 h after administration and peaked at 7-fold 
control levels 24 h after administration [ 11. As part 
of our study on the mode of action of anti-oestrogens 
we here describe a comparison of the effects of oestro- 
gen and tamoxifen on the incorporation of precursor 
into purified high M, uterine RNA. 
2. Materials and methods 
The administration of tamoxifen and oestradiol- 
170 by subcutaneous injection in corn oil has been 
described [ 11. The purification ofhighMr uterine RNA 
and its fractionation and analysis on 2.7% polyacryla- 
mide gels has been described [ 21. 
Abbreviations: hnRNA, heterogeneous nuclear RNA, pre- 
IRNA, precursors to ribosomal RNA; Oestradiol-17p, 
1,3,5(10)estratriene-3,17fldiol,Tamoxifen, [ 144$dimethyl- 
aminoethoxyphenyl) 1,2diphenylbut-lene] 
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3. Results and discussion 
Fig.1 shows the incorporation of precursor into 
the high&f, uterine RNAof untreated (received carrier 
only),3-week-old 30-35 g rats. The result revealsvery 
little incorporation and confirms our findings that the 
uterus of the immature rat is a very quiescent tissue. 
It synthesizes little RNA [2], little protein [4] and 
most of its ribosomes are in the form of monosomes 
[4]. Fig.1 illustrates the results obtained when carrier 
was administered 2 h before death but essentially 
identical results were obtained when it was given 12 h 
and 24 h before death or if no carrier was administered. 
Fig.2 shows the effect of oestrogen, tamoxifen and 
a combination of oestrogen and tamoxifen on the 
incorporation of precursor into high M,, uterine RNA 
which has been fractionated on 2.7% polyacrylamide 
gels. It can be seen that, 2 h after the administration 
of 11.18 oestradiol-17/3/30-3 5 g rat, there was a marked 
stimulation in the incorporation of precursor into 
28 S and 18 S RNA. This increased synthesis could be 
followed through the 45 S and 32 S pre-rRNA species 
by varying the time of precursor incorporation and 
by cofractionating with 14C-labelled 45 S and 32 S 
RNA isolated from HeLa cell nucleoli [2]. The 32 S 
species is detectable in the 2 h oestrogen treatment 
panel of fig.2 as a peak of radioactivity migrating 
slightly slower than the 28 S species. The 45 S species 
was most clearly defined in experiments where the 
radioactive precursor was administered 15 min before 
death (not shown). Clearly, the synthesis of uterine 
rRNA is strongly stimulated at 2 h after oestrogen 
administration and the response appears to result from 
increased transcription of the 45 S rRNA precursor. 
These results confirm [2]. It is notable that the peaks 
of radioactive precursor incorporation into rRNA and 
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Fig.1. The incorporation of precursor into the high Mr RNA 
of immature rat uterus. Eight 19-21dayold rats, (30-35 g) 
received a subcutaneous injection of 0.1 ml comoil2 h before 
death. They subsequently received 100 &i each of [5-‘HI- 
uridine and [8-“Hlguanosine (each at 5 Ci/mmol) in 0.2 ml 
09% NaCl by lateral tail-vein injection 30 mm before death. 
Uterine high Mr RNA was then purified and 80 clg was frac- 
tionated on 2.7% polyacrylamide gels, scanned at an extinc- 
tion of 260 nm, the gel sliced into 1 mm sections and the radio- 
activity in each slice determined as in section 2. (-) Ez6,,; 
(---) radioactivity in dpm/slice. For reasons of clarity, the 
E,,, trace is omitted for the fast few slices of the gels. 
pre-rRNAare superimposed on a background of incor- 
poration into other high M, RNA species. Extensive 
characterization and fractionation studies conducted 
by this laboratory in the past have shown that these 
species are of nuclear location, have a rapid turnover, 
lack methylation, contain poly (A) sequences and a 
base composition that identifies them as hnRNA [ 5,6]. 
We have further shown that oestrogen-induced hnRNA 
synthesis precedes and is a pre-requisite for the sub- 
sequent stimulation of rRNA synthesis [5-71. 
The marked stimulation of RNA synthesis in imma- 
ture rat uterus peaks at 2-4 h after a single injection 
of oestradioLl7fl and then rapidly falls off, presumably 
due to hormone metabolism [ 1,3]. Fig.2 shows the 
incorporation of precursor into high Mr uterine RNA 
at 12 and 24 h after oestradioLl7fl administration 
and it is seen that synthesis is much reduced by 12 h 
and, by 24 h, rRNA synthesis has returned almost to 
control levels although some stimulation of hnRNA 
synthesis is still observed (fig.2). 
Tamoxifen alone had no significant effect on in vivo 
uterine RNA synthesis when administered 2 h before 
death (fig.2). This finding contrasted with in vitro 
analyses which have examined RNA polymerase activ- 
ity in isolated uterine nuclei [8,9]. In these analyses 
some effects of tamoxifen on enzyme activity were 
observed though the stimulation was less marked than 
that induced by oestrogen. Considerable stimulation 
of the incorporation of precursor into high Mr uterine 
RNA was observed at 12 and 24 h after the adminis- 
tration of tamoxifen (fig.2). This confirmed our pre- 
vious findings on the incorporation of precursor into 
acid-insoluble material [ 11. As in the earlier stimula- 
tion of RNA synthesis by oestrogen, rRNA, pre-rRNA 
and hnRNA appear to be involved in the response 
(fig.2). 
The slower response in the rat uterus responding 
to tamoxifen may reflect its low rate of metabolism 
compared with that of oestradiol. The half-life of 
tamoxifen in human blood is 4 days compared with 
Fig.2. The incorporation of precursor into the high Mr uterine RNA of immature rats responding to oestrogen and tamoxifen. 
Groups of eight 19-21dayold rats (30-35 g) received subcutaneous injections of 0.1 ml corn oil in which was dissolved 1.0 ng 
oestradiol-17p or 30 pg tamoxifen or a combination of both at 2,12 or 24 h before death. They subsequently received radioactive 
RNA precursor 30 mm before death and high M, uterine RNA was prepared and analyzed as in fig.1. (-) E,,,; (---) radioac- 
tivity in dpm/sJice. For reasons of clarity, the E,,, trace is omitted for the first few slices of the gels. 
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<6 h for oestradiol [IO]. The accumulation of tam- 
oxifen in target cell nuclei is also much slower than 
that of oestrogen, though its nuclear retention is much 
increased. Thus, oestradiol nuclear concentration is 
maximal 2 h after its injection while tamoxifen con- 
centration peaks at 24 h after administration [ 121. 
Nuclear oestradiol levels have returned to those of 
untreated controls by 24 h after injection whereas 
tamoxifen is still present in nuclei 4 days after admin- 
istration [ 121. It is not clear, however, whether the 
prolonged nuclear retention is merely a reflection of 
the long half-life in blood. 
Tamoxifen is an anti-oestrogen which competes 
with the hormone for its receptor [ 121, is carried as a 
receptor complex to the nucleus [ 11 ,131 and is 
assumed to competitively inhibit oestrogeninduced 
nuclear events. Fig.2 shows the results obtained when 
tamoxifen was administered together with oestradiol- 
170 2,12 and 24 h prior to death. It can be seen that 
the anti-oestrogen was unable to totally inhibit oestro- 
gen-induced nuclear events. Thus it was only partially 
able to inhibit oestrogen-induced RNA synthesis 2 h 
after administration. Stimulated synthesis of both 
rRNA and hnRNA was again seen 12 h after the simul- 
taneous administration of oestrogen and tamoxifen. 
In view of the effects of the individually administered 
compounds, this was assumed to be caused by tam- 
oxifen rather than oestradioll7fl. At 24 h after the 
joint administration, very little RNA synthesis was 
observed. This again confirms our observations of pre- 
cursor incorporation into acid-insoluble material [l] 
and suggests that, at this time, oestrogen may be acting 
as a tamoxifen inhibitor rather than the reverse. 
The results presented reveal that the mode of action 
of tamoxifen is complex and that it certainly does 
not totally inhibit oestrogen-induced RNA synthesis. 
It is hoped that further studies on the effect of the 
inhibitor on oestrogen-induced changes in mRNA 
populations and in oestrogen-induced ribosome accu- 
mulation will clarify the site of action of the com- 
pound. 
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